No revenue or near-term catalyst announced — the stock will trade on pipeline sentiment and cash runway. Key catalysts to watch: mid-2026 site activation for EB06 vitiligo Phase 2, and any paridiprubart partnership or regulatory pathway updates. With $10M cash and $4.1M H1 burn, the company has ~7 quarters of runway, reducing near-term dilution risk.
Price Chart
Executive Summary
Edesa Biotech reported fiscal Q2 2026 results with a net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/share) a year ago, driven by increased R&D spending on EB06 vitiligo program preparations. Cash burn reduced cash to $10.0M from $12.1M at prior quarter-end, providing roughly 7 quarters of runway at current burn rates. The company reaffirmed mid-2026 site activation guidance for the Phase 2 vitiligo study and highlighted consistent Phase 3 paridiprubart data across subgroups, but no revenue or near-term catalysts were announced.
Key Financial Metrics
Key Facts
- Net loss of $4.2M for Q2 2026 vs $1.6M in Q2 2025, driven by R&D ramp for EB06 vitiligo program
- Cash and cash equivalents of $10.0M at March 31, 2026, down from $12.1M at December 31, 2025
- Operating cash burn of $4.1M for H1 2026 vs $3.9M for H1 2025
- Reaffirmed guidance: site activations and patient recruitment for Phase 2 vitiligo study expected mid-2026
- Announced additional positive Phase 3 paridiprubart data showing consistent benefits across disease severity subgroups
- No revenue reported; pre-revenue clinical-stage biopharma company
Financial Impact
Net loss widened to $4.2M from $1.6M YoY; cash burn $4.1M in H1 2026; cash runway ~7 quarters at current burn
Risk Factors
- Cash burn rate increasing as EB06 program ramps; may require additional financing within 12-18 months
- No approved products or revenue; entirely dependent on clinical trial success
- Phase 2 vitiligo study has not yet begun enrollment; regulatory approvals still pending
- Paridiprubart ARDS program requires additional funding or partnership for commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003429 |
| Document: f8k_051326.htm | 0001171843-26-003429 |
| Document: 0001171843-26-003429-index-headers.html | 0001171843-26-003429 |
| Document: 0001171843-26-003429-index.html | 0001171843-26-003429 |
| Document: 0001171843-26-003429.txt | 0001171843-26-003429 |
| 8-K Data (Synthetic) | 0001171843-26-003429 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.59 | awaiting T+20 | — | $2.63 (+1.54%) |
Oct 15, 2026 12d ago | 8-K | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Oct 15, 2026 12d ago | Press Release | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Aug 19, 2026 9w ago | Press Release | $4.76 $4.14 | ▲ +13.03% | ▲ +13.03% | $2.63 (+44.75%) |
Jul 14, 2026 15w ago | EFFECT | $6.74 $5.52 | ▲ +18.10% | ▲ +20.59% | $2.63 (+60.98%) |
Jul 2, 2026 16w ago | S-3 | $7.50 $5.25 | ▼ −30.00% | ▼ −29.59% | $2.63 (−64.93%) |
Jun 5, 2026 20w ago | 8-K | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
Jun 5, 2026 20w ago | Press Release | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
May 29, 2026 21w ago | 8-K | $6.69 $8.13 | ▲ +21.52% | ▲ +22.82% | $2.63 (−60.69%) |
May 19, 2026 23w ago | Press Release | $11.95 $6.88 | ▼ −42.43% | ▼ −43.41% | $2.63 (−77.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers